Nanocarrier-based topical drug delivery for the treatment of skin diseases

Expert Opinion on Drug Delivery

Volumn 9, Issue 7, 2012, Pages 783-804

  Gupta, Madhu ^a   Agrawal, Udita ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

nanocarriers; skin; skin disorders; topical delivery

Indexed keywords

ACECLOFENAC; AMPHOTERICIN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOTRIMAZOLE; DICLOFENAC; ECONAZOLE; EUGENOL; FLUCONAZOLE; INSULIN; KETOCONAZOLE; KETOPROFEN; LIPOSOME; METHOTREXATE; MICONAZOLE; MICONAZOLE NITRATE; MINOXIDIL; NANOCARRIER; PREDNICARBATE; RETINOIC ACID; RIBOFLAVIN; SKIN LIPID; SPANTIDE; SULCONAZOLE; TACROLIMUS; TAXIFOLIN; TAZAROTENE; UNINDEXED DRUG; VORICONAZOLE;

ALOPECIA; ANDROGENIC ALOPECIA; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; CANDIDIASIS; DERMATOMYCOSIS; DERMATOPHYTOSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; EPIDERMIS; HAIR FOLLICLE; HUMAN; KERATINOCYTE; MYCOSIS; NANOEMULSION; NANOMEDICINE; NONHUMAN; OSTEOARTHRITIS; PARTICLE SIZE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANDIDIASIS; SKIN DEFECT; SKIN DISEASE; SKIN INFLAMMATION; SKIN INJURY; SKIN PENETRATION; SKIN STRUCTURE; SKINFOLD THICKNESS; STRATUM CORNEUM; SUBCUTANEOUS FAT; SUPERFICIAL MYCOSIS; SUSTAINED DRUG RELEASE; TREATMENT INDICATION; VITILIGO;

ADMINISTRATION, CUTANEOUS; DRUG CARRIERS; HUMANS; NANOPARTICLES; SKIN; SKIN ABSORPTION; SKIN DISEASES;

EID: 84862733885     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.686490     Document Type: Review

References (125)

1. Sigmundsdottir H. Improving topical treatments for skin Diseases. Trends Pharmacol Sci 2010;31:239-45
2. Fleischer AB Jr, Feldman SR, Rapp SR. The magnitude of skin disease in the United States. Dermatol Clin 2000;18:xv-xxi (Pubitemid 30220633)
3. Dawson AL, Robert PD, Dirk ME. Infectious skin diseases: a review and needs assessment. Dermatol Clin 2012;30:141-51
4. Roberts MS, Walters KA. Human skin morphology and dermal absorption. In: Roberts MS, Walters KA, editors. Dermal Absorption and Toxicity Assessment. Informa Healthcare, New York; 2008. p. 1-15
5. Bissett DL. Anatomy and biochemistry of the skin. In: Kydonieus F, Berner B, editors. Transdermal Delivery of Drugs. Volume 1 CRC Press, Inc., Boca Raton; 1987. p. 29-42
6. Erdogan S. Liposomal nanocarriers for tumor imaging. J Biomed Nanotechnol 2009;5:141-50
7. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002;54:41-55
8. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011;63:470-91
9. Merwe D, van der, Brooks JD, Gehring R, et al. A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicol Sci 2006;89:188-204
10. Langbein L, Grund C, Kuhn C, et al. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived there from. Eur J Cell Biol 2002;81:419-35 (Pubitemid 34982270)
11. Schaefer H, Redelmeier TE. Skin Barrier: Principles of Percutaneous Absorption. Karger, Basel; 1996
12. Barry BW. Dermatological Formulations: Percutaneous Absorption. Marcel Dekker, New York; 1983
13. Suzanne MB, Zhi D, Elly R, et al. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010;148:266-82
14. Robert EM, Kalia YN. New developments in topical antifungal therapy. Am J Drug Deliv 2006;4:231-47
15. Gabard B, Elsner P, Surber C, Treffel P. Dermatopharmacology of Topical Preparations: a Product-Development Oriented Approach. Springer-Verlag, Berlin; 2000
16. Dancik Y, Jepps OG, Roberts MS. Beyond stratum corneum. In: Roberts MS, Walters KA, editors. Dermal Absorption and Toxicity Assessment. Informa Healthcare, Inc., New York; 2008. p. 209-50
17. Garcia OP, Hansen SH, Shah VP, et al. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol 2009;89:33-8
18. Jensen LB, Petersson K, Nielsen HM. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin. Eur J Pharm Biopharm 2011;79:68-75
19. Nacht S, Katz M. The microsponge: A novel topical programmable delivery system. In: Osborne DW, Amman AH, editors. Topical Drug Delivery Formulations. Marcel Dekker Basel, New York; 1990. p. 299-325
20. Pradhan SK. Microsponges as the versatile tool for drug delivery system. Int J Res Pharm Chem 2011;1:243-58
21. Barry BW. Penetration enhancers. In: Shroot B, Schafer H, editors. Skin Pharmacokinetics. Karger, Basel; 1987. p. 121-7
22. Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev 1996;18:335-42 (Pubitemid 26063307)
23. Teichmann A, Heuschkel S, Jacobi U, et al. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm 2007;66:159-64
24. Castro GA, Coelho ALLR, Oliveira CA, et al. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm 2009;381:77-83
25. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012. doi:10.1016/j. chemphyslip.2012.01.006 This study reported that NLCs provide a good skin-targeting effect and may be a promising carrier for topical delivery of fluconazole, offering the sustained release and maintaining the localized effect, resulting in an effective treatment of a life-threatening cutaneous fungal infection.
26. Pople PV, Singh KK. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm 2011;79:82-94
27. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomed Nanotechnol Biol Med 2008;4:273-82 This review will provide a brief discussion of the major nanopharmaceutical formulations as well as the impact of nanotechnology into the future.
28. Zhang L, Pornpattananangkul D, Hu CMJ, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010;17:585-94
29. Katahira N, Murakami T, Kugai S, et al. Enhancement of topical delivery of a lipophilic drug from charged multilamellar liposomes. J Drug Target 1999;6:405-14 (Pubitemid 29452684)
30. Martin P, Youenang P, Daniel K, Simon B. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs. J Control Release 1999;58:177-87 (Pubitemid 29112888)
31. Vanniasinghe AS, Bender V, Manolios N. The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum 2009;39:182-96
32. Tamilvanan S, Venkateshan N, Ludwig A. The potential of lipid-and polymer-based drug delivery carriers for eradicating biofilm consortia on device-related nosocomial infections. J Control Release 2008;128:2-22
33. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release 1994;30:l-15
34. Gupta M, Goyal AK, Paliwal SR, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res 2010;20:341-50
35. Mezei M, Gulasekharam V. Liposomes - a selective drug delivery system for the topical route of administration: lotion dosage form. Life Sci 1980;26:1473-7 (Pubitemid 10042852)
36. Trapasso E, Cosco D, Celia C, et al. Retinoids: new use by innovative drug-delivery systems. Expert Opin Drug Deliv 2009;5:465-83
37. Kirjavainen M, Urtti A, Jaaskelainen I, et al. Interaction of liposomes with human skin in vitro - the influence of lipid composition and structure. Biochim Biophys Acta 1996;1304:179-89 (Pubitemid 26426990)
38. El Maghraby GM, Williams AC, Barry BW. Can drug bearing liposomes penetrate intact skin? J Pharm Pharmacol 2006;58:415-29
39. Skalko N, Cajkovac M, Jalsenjak I. Liposomes with clindamycin hydrochloride in therapy of acne vulgaris. Int J Pharm 1992;85:97-101
40. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes: in vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm 2006;323:1-10 (Pubitemid 44397357)
41. Montenegro L, Panico AM, Ventimiglia A, Bonina FP. In vitro retinoic acid release and skin permeation from different liposome formulations. Int J Pharm 1996;133:89-96 (Pubitemid 26160838)
42. Sinico C, Manconi M, Peppi M, et al. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release 2005;103:123-36 (Pubitemid 40248567)
43. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-388 (Pubitemid 27024259)
44. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol 2005;2:67-74 (Pubitemid 40946310)
45. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004;270:119-25 (Pubitemid 38077093)
46. Boinpally RR, Zhou SL, Poondru S, et al. Lecithin vesicles for topical delivery of diclofenac. Eur J Pharm Biopharm 2003;56:389-92 (Pubitemid 37346512)
47. Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, transfersomes. Biochim Biophys Acta 2001;1514:191-205 (Pubitemid 32831008)
48. Elsayed MAA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007;332:1-16 (Pubitemid 46237706)
49. El Maghraby GM, Williams AC, Barry BW. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J Pharm Pharmacol 2001a;53:1069-77 (Pubitemid 32754937)
50. Trotta M, Peira E, Debernardi F, Gallarate M. Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int J Pharm 2002;241:319-27 (Pubitemid 34718033)
51. Touitou E, Dayan N, Bergelson L, et al. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000;65:403-18 (Pubitemid 30122942)
52. Liu J, Hu G. Advances in studies of phospholipids as carriers in skin topical application. J Nanjing Med Uni 2007;21:349-53
53. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14 (Pubitemid 32737532)
54. Godin B, Touitou E. Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier. J Control Release 2004;94:365-79 (Pubitemid 38117147)
55. Paolino D, Lucania G, Mardente D, et al. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release 2005;106:99-110 (Pubitemid 41140085)
56. Manconi M, Sinico C, Caddeo C, et al. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int J Pharm 2011;412:37-46 Penetration enhancer containing vesicles seem to be the most appropriate formulations for tretinoin dermal delivery. This investigation reported that drug deposition and permeation in the skin was found to be affected by PEV composition.
57. Mura S, Manconi M, Sinico C, et al. Transcutol containing vesicles for topical delivery of minoxidil. J Drug Target 2011;19:189-96
58. Song CK, Balakrishnan P, Shim C, et al. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces 2012;1:299-304 The transethosomes enhanced both in vitro and in vivo skin deposition of voriconazole in the dermis/epidermis region compared with other one. Therefore, this novel carrier transethosomes could serve as an effective dermal delivery for voriconazole.
59. Bird DK, Schneider AL, Watkinson AC, et al. Navigating transdermal diffusion with multiphoton fluorescence lifetime imaging. J Microsc 2008;230:61-9 (Pubitemid 351489991)
60. Barbara G, Van GM, Sien B, Stefaan C. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater 2010;20:4077-90
61. Shah AK, Date AA, Joshi MD, Patraval VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 2007;345:163-71 (Pubitemid 350087549)
62. Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol 2011; doi:10.3109/10837450.2011.598161
63. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 2008;363:132-8
64. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77 (Pubitemid 30326695)
65. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84
66. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-7 (Pubitemid 38670438)
67. Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501-10 (Pubitemid 43123888)
68. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008;346:124-32 (Pubitemid 350110507)
69. Teeranachaideekul V, Boonme P, Souto EB, et al. Influence of oil content on physicochemical properties and skin distribution of nile red-loaded NLC. J Control Release 2008;128:134-41
70. Stecova J, Mehnert W, Blaschke T, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007;24:991-1000 (Pubitemid 46675401)
71. Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008;68:453-66 (Pubitemid 351318206)
72. Santos MC, Mehnert W, Schaller M, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002;10:489-95 (Pubitemid 35230199)
73. Hu FQ, Jiang SP, Du YZ, et al. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 2006;314:83-9
74. Sivaramakrishnan R, Nakamura C, Mehnert W, et al. Glucocorticoid entrapment into lipid carriers characterization by parelectric spectroscopy and influence on dermal uptake. J Control Release 2004;97:493-502 (Pubitemid 38802951)
75. Wissing S, Lippacher A, Muller A. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 2001;52:313-24 (Pubitemid 33724124)
76. Fang JY, Fang C, Liu C-H, Su Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008;70:633-40 The study indicated that the NLCs can potentially be exploited as carriers with improved drug permeation for psoriasis therapies.
77. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials 2012;33:1607-17
78. Senyigit T, Sonvico F, Barbieri S, et al. Lecithin/Chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Control Release 2010;142:368-73
79. Alvarez-Roman R, Naik A, Kalia YN, et al. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004;21:1818-25 (Pubitemid 39390094)
80. Luengo J, Weiss B, Schneider M, et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 2006;19:190-7 (Pubitemid 44114517)
81. Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int J Pharm 2010;401:72-8
82. Batheja P, Sheihet L, Kohn J, et al. Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J Control Release 2011;149:159-67
83. Abdel-Mottaleb MMA, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm 2011;79:36-42 This investigation presented that the lipid nanocapsules can be considered as efficient as SLNs and NLCs for the transdermal drug delivery while polymeric nanoparticles are more suitable for localized drug delivery to the skin.
84. Bachhav YG, Mondon K, Kalia YN, et al. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Control Release 2011;153:126-32
85. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003;258:141-51 (Pubitemid 36712878)
86. Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid--polymer hybrid nanoparticles. Colloids Surf B Biointerfaces 2011;85:214-20
87. El laithy HM, El-Shaboury KMF. The development of cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech 2002;3:1-9
88. Murdan S, Gregoriadis G, Florence AT. Novel sorbitan monostearate organogels. J Pharm Sci 1999;88:608-14 (Pubitemid 29260783)
89. Salerno C, Carlucci AM, Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS PharmSciTech 2010;11:986-93
90. Peira E, Carlotti ME, Trotta C, et al. Positively charged microemulsions for topical application. Int J Pharm 2008;346:119-23 This study suggests that positively charged microemulsions could be used to optimize drug targeting without a concomitant increase in systemic absorption. (Pubitemid 350101984)
91. Patel MR, Patel RB, Parikh JR, et al. Investigating the effect of vehicle on in vitro skin permeation of ketoconazole applied in O/W microemulsions. Acta Pharmaceutica Sciencia 2010;52:65-77
92. Dima S, Popescu M. Topical delivery of diclofenac using microemulsion systems. Roumanian Biotech Lett 2008;13:49-55
93. Lee EA, Balakrishnan P, Song CK, et al. Microemulsion-based hydrogel formulation of itraconazole for topical delivery. J Pharm Invest 2010;40:305-11
94. Shah RR, Magdum CS, Patil SS, Niakwade NS. Preparation and evaluation of aceclofenac topical microemulsion. J Pharm Res 2010;9:5-11
95. Charles L, Matthew D. Cardiac glycosides for treating muscle pain and spasm. US20030229029; 2003
96. Hirlekar R, Jain S, Patel M, et al. Hexosomes: a novel drug delivery system. Curr Drug Deliv 2010;7:28-35 This report concluded that special properties of hexosomes are used to improve solubility of poorly water-soluble drugs and to transport therapeutic moiety by transdermal route.
97. Thadanki M, Srivalli P, Prabha K. Overview of cubosomes: a nano particle. Int J Res Pharm Chem 2011;1:535-41
98. Elisabetta E, Carmelo P, Markus D, Lydia P. Production and characterization of cubosomes: a new tool for percutaneous administration of lipophilic drugs. Proc. 5th world meetings. Pharm Biopharm Pharm Technol 2006;1-2
99. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004;56:675-711 (Pubitemid 38326939)
100. Hofland HEJ, Bouwstra JA, Bodde HE, et al. Interaction between liposomes and human stratum corneum in vitro: freeze fracture electron microscopical visualization and small angle X-ray scattering studies. Br J Dermatol 1995;132:853-66
101. Schaller M, Korting HC. Interaction of liposomes with human skin: the role of the stratum corneum. Adv Drug Deliv Rev 1996;18:303-9 (Pubitemid 26062290)
102. Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J Microencapsul 1990;7:479-89
103. Korting HC, Zeinicke H, Schafer KM, Falco OB. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990;39:349-51 (Pubitemid 20362344)
104. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 2007;62:133-7 (Pubitemid 46279965)
105. Valenta C, Janisch M. Permeation of cyproterone acetate through pig skin from different vehicles with phospholipids. Int J Pharm 2003;258:133-9 (Pubitemid 36712877)
106. Mura S, Manconi M, Sinico C, et al. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Int J Pharm 2009;380:72-9
107. Vogt A, Combadiere B, Hadam S, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006;126:1316-22 (Pubitemid 43997914)
108. Manconi M, Caddeo C, Sinico C, et al. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle-skin interaction. Eur J Pharm Biopharm 2011;78:27-35 This work shows the superior ability of the PEVs to enhance ex vivo drug transport of both hydrophilic and lipophilic diclofenac forms.
109. Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomed Nanotechnol Biol Med 2011. doi:10.1016/j.nano.2011.07.004 The results suggest that because of the controlled drug release, better antifungal activity and good storage stability, econazole-loaded ethosomal gel has tremendous potential to serve as a topical delivery system.
110. Bhalaria MK, Naik S, Misra AN. Ethosomes a novel delivery system for antifungal drug in the treatment of topical fungal diseases. Indian J Exp Biol 2009;47:368-75
111. El Zaafarany GM, Awad GAS, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm 2010;397:164-72
112. Kang MJ, Kang MJ, Eum JY, et al. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm 2010;402:198-204
113. Higa Leticia H, Priscila S, Ana PP, et al. Ultradeformable archaeosomes as new topical adjuvants. Nanomed Nanotechnol Biol Med 2012. doi.org/10.1016/j.nano.2012.02.008
114. Cirri M, Bragagni M, Mennini N, Mura P. Development of a new delivery system consisting in "drug - in cyclodextrin - in nanostructured lipid carriers" for ketoprofen topical delivery. Eur J Pharm Biopharm 2012;80:46-53
115. Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010;398:165-78
116. Garg A, Singh S. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers. Colloids Surf B Biointerfaces 2011;87:280-8
117. Mitri K, Shegokar R, Gohla S, et al. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Int J Pharm 2011;414:267-75
118. Yordanov G. Influence of the preparation method on the physicochemical properties of econazole-loaded poly (butyl cyanoacrylate) colloidal nanoparticles. Colloids Surf A Physicochem Eng Aspects 2012. doi.org/10.1016/j.colsurfa.2011.12.060
119. Shah PP, Desai PR, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Rel 2012;158:336-45
120. Ourique AF, Melero A, Bona da Silva C, et al. Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicines. Eur J Pharm Biopharm 2011;79:95-101
121. Filipowicz A, Wołowiec S. Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM Dendrimers. Int J Pharm 2011;408:152-6
122. Ali J, Akhtar N, Sultana Y, et al. Antipsoriatic microemulsion gel formulations for topical drug delivery of babchi oil (Psoralea corylifolia). Methods Find Exp Clin Pharmacol 2008;30:277-85
123. Modi JD, Patel JK. Nanoemulsion-based gel formulation of aceclofenac for topical delivery. Int J Pharm Pharm Sci Res 2011;1:6-12
124. Michael H, Manuela M-G, Barron Annelise E, et al. Sustained prolonged topical delivery of bioactive human insulin for potential treatment of cutaneous wounds. Int J Pharm 2010;398:146-54
125. Baspinar Y, Borchert H. Penetration and release studies of positively and negatively charged nanoemulsions - is there a benefit of the positive charge? Int J Pharm 2012. doi.org/10.1016/j.ijpharm.2012.03.040